Toreforant (JNJ-38518168) is an orally-dosed selective antagonist of the histamine H4 receptor that has been studied for various health conditions.

[1] Phase IIa clinical trials completed as recently as November 2018 continue to suggest that toreforant is safe.

Phase II clinical trials, toreforant, by itself, did not show efficacy against eosinophilic asthma.

[2] The drug did show at least partial efficacy against rheumatoid arthritis in patients who were nonresponsive to methotrexate.

[3] As the H4 receptor is widely implicated in the regulation of inflammatory states, the potential uses for an H4 antagonist remain significant.